JPWO2020055824A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020055824A5 JPWO2020055824A5 JP2021538171A JP2021538171A JPWO2020055824A5 JP WO2020055824 A5 JPWO2020055824 A5 JP WO2020055824A5 JP 2021538171 A JP2021538171 A JP 2021538171A JP 2021538171 A JP2021538171 A JP 2021538171A JP WO2020055824 A5 JPWO2020055824 A5 JP WO2020055824A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- item
- amino acid
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 102
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 20
- 238000011191 terminal modification Methods 0.000 claims description 12
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 6
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 150000008575 L-amino acids Chemical class 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 3
- 208000032376 Lung infection Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 3
- 231100000515 lung injury Toxicity 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 238000000498 ball milling Methods 0.000 claims description 2
- 230000008512 biological response Effects 0.000 claims description 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000010902 jet-milling Methods 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 239000000779 smoke Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 238000001238 wet grinding Methods 0.000 claims description 2
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 238000002663 nebulization Methods 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- -1 DMARD Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024106451A JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729010P | 2018-09-10 | 2018-09-10 | |
| US62/729,010 | 2018-09-10 | ||
| PCT/US2019/050349 WO2020055824A1 (en) | 2018-09-10 | 2019-09-10 | Dry powder formulation of caveolin-1 peptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024106451A Division JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500500A JP2022500500A (ja) | 2022-01-04 |
| JP2022500500A5 JP2022500500A5 (https=) | 2022-09-09 |
| JPWO2020055824A5 true JPWO2020055824A5 (https=) | 2022-09-09 |
| JP7514840B2 JP7514840B2 (ja) | 2024-07-11 |
Family
ID=69778150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538171A Active JP7514840B2 (ja) | 2018-09-10 | 2019-09-10 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
| JP2024106451A Pending JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024106451A Pending JP2024114982A (ja) | 2018-09-10 | 2024-07-01 | カベオリン－１ペプチドの乾燥粉末製剤およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US12280088B2 (https=) |
| EP (1) | EP3849581A4 (https=) |
| JP (2) | JP7514840B2 (https=) |
| KR (1) | KR20210057127A (https=) |
| CN (2) | CN112996530B (https=) |
| AU (1) | AU2019339264B2 (https=) |
| BR (1) | BR112021004420A2 (https=) |
| CA (1) | CA3109982A1 (https=) |
| WO (1) | WO2020055824A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110201144B (zh) | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| WO2016138413A1 (en) * | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Polypeptide therapeutics and uses thereof |
| AU2019339260B2 (en) | 2018-09-10 | 2025-06-26 | Rein Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
| US20240082342A1 (en) * | 2018-11-21 | 2024-03-14 | Board Of Regents, The University Of Texas System | Peptide therapeutics for increasing lung cell viability |
| US20220370544A1 (en) * | 2018-11-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Peptide therapeutics for acute and chronic airway and alveolar diseases |
| WO2020185826A1 (en) * | 2019-03-11 | 2020-09-17 | Lung Therapeutics, Inc. | Compositions and methods for protecting type 2 alveolar epithelial cells (aec2) |
| EP4138791A1 (en) * | 2020-04-20 | 2023-03-01 | Board of Regents, The University of Texas System | Biologically active dry powder compositions and method of their manufacture and use |
| US20230159608A1 (en) * | 2020-04-21 | 2023-05-25 | Lung Therapeutics, Inc. | Modified peptide fragments of cav-1 protein and uses thereof |
| US20230226149A1 (en) * | 2020-06-19 | 2023-07-20 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury |
| US20250041383A1 (en) * | 2021-06-17 | 2025-02-06 | Lung Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of post-acute covid-19 |
| US20250262273A1 (en) * | 2021-10-22 | 2025-08-21 | Rein Therapeutics, Inc. | Modified caveolin-1 peptides for the treatment of chronic kidney disease |
| EP4719450A2 (en) * | 2023-05-30 | 2026-04-08 | Rein Therapeutics, Inc. | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof |
| CN121695995A (zh) * | 2024-09-18 | 2026-03-20 | 深圳翰宇药业股份有限公司 | 一种多肽药物的粉碎方法 |
| CN119661656A (zh) * | 2024-11-20 | 2025-03-21 | 华中科技大学同济医学院附属梨园医院 | 一种靶向拮抗pCAV1的多肽及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| IT1190891B (it) | 1982-06-24 | 1988-02-24 | Anic Spa | Metodo per la sintesi in fase solida di polipeptidi retroinvertiti |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| CN1091138A (zh) | 1992-08-27 | 1994-08-24 | 迪金研究有限公司 | 疫苗 |
| US20020077283A1 (en) * | 2000-09-08 | 2002-06-20 | Sessa William C. | Caveolin peptides and their use as therapeutics |
| GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
| EP1501479A1 (en) | 2002-05-07 | 2005-02-02 | Nektar Therapeutics | Capsules for dry powder inhalers and methods of making and using same |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US7625865B2 (en) | 2004-03-26 | 2009-12-01 | Universita Degli Studi Di Parma | Insulin highly respirable microparticles |
| EP2074142A4 (en) * | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| EP2635686B1 (en) | 2010-11-05 | 2018-03-28 | The Regents of The University of California | Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
| BR112015022831A2 (pt) | 2013-03-13 | 2017-08-22 | Forest Laboratories Holdings Ltd | Composições farmacêuticas micronizadas |
| CN110201144B (zh) * | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| WO2015080980A2 (en) | 2013-11-26 | 2015-06-04 | E&B Technologies Llc | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators |
| EP3262856B1 (en) * | 2015-02-27 | 2020-02-19 | PCMS Holdings, Inc. | Systems and methods for secure roll-over of device ownership |
| WO2016138413A1 (en) * | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Polypeptide therapeutics and uses thereof |
-
2019
- 2019-09-10 KR KR1020217010694A patent/KR20210057127A/ko not_active Ceased
- 2019-09-10 WO PCT/US2019/050349 patent/WO2020055824A1/en not_active Ceased
- 2019-09-10 CN CN201980073144.0A patent/CN112996530B/zh active Active
- 2019-09-10 JP JP2021538171A patent/JP7514840B2/ja active Active
- 2019-09-10 AU AU2019339264A patent/AU2019339264B2/en active Active
- 2019-09-10 CA CA3109982A patent/CA3109982A1/en active Pending
- 2019-09-10 US US17/274,666 patent/US12280088B2/en active Active
- 2019-09-10 CN CN202510651536.8A patent/CN120459067A/zh active Pending
- 2019-09-10 BR BR112021004420-5A patent/BR112021004420A2/pt unknown
- 2019-09-10 EP EP19859836.9A patent/EP3849581A4/en active Pending
-
2024
- 2024-02-06 US US18/434,731 patent/US12280089B2/en active Active
- 2024-07-01 JP JP2024106451A patent/JP2024114982A/ja active Pending
-
2025
- 2025-03-19 US US19/083,757 patent/US20250302910A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100291620B1 (ko) | 부갑상선호르몬의활성단편의폐를통한전달방법 | |
| JPWO2020055824A5 (https=) | ||
| JP2986215B2 (ja) | Ｄｎアーゼ含有医薬製剤 | |
| US20140302151A1 (en) | Methods and compositions for treating pain | |
| JP2020502121A5 (https=) | ||
| JPH09500621A (ja) | 吸入用組成物 | |
| JP5405307B2 (ja) | 改善された性質を有する再構成サーファクタント | |
| KR20120028892A (ko) | 계면 활성 단백질 ｂ (ｓｐ－ｂ) 및 계면 활성 단백질 ｃ (ｓｐ－ｃ)의 유사체를 함유하는 개량된 재구성 계면 활성제 조성물 | |
| KR20010073033A (ko) | 인슐리노트로픽 펩티드의 투여 방법 | |
| JPH10511090A (ja) | 副甲状腺ホルモン，ｐｔｈ含有吸入用治療製剤 | |
| JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
| JP2022500078A5 (https=) | ||
| EP1694314A1 (en) | Treatment and preventions of asthma | |
| JP6397984B2 (ja) | 乾燥粉末ペプチド医薬 | |
| JP2023071886A5 (https=) | ||
| JP2005537296A5 (https=) | ||
| WO2022116792A1 (zh) | 一种用于治疗肺结核的异烟肼干粉吸入剂 | |
| JP2019518782A (ja) | 吸入用サーファクタント製剤 | |
| RS55154B1 (sr) | Interferon beta za upotrebu u lečenju bolesti donjeg respiratornog trakta uzrokovane gripom | |
| WO2014094230A1 (zh) | Sp肽或其衍生物在制备预防或治疗哮喘的药物中的应用 | |
| CN119156396A (zh) | 用于治疗covid感染的方法和组合物 | |
| JPH07509714A (ja) | ペプチド肺表面活性剤及び治療用組合せ | |
| CN118695855A (zh) | 通过单次鼻内施用用于鼻和肺沉积的抗病毒剂的双重靶向粉末制剂 | |
| JP2023521412A (ja) | 肺疾患を治療及び予防するための組成物及び方法 | |
| KR20100123240A (ko) | 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법 |